# A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

> **NCT07101939** · PHASE2 · RECRUITING · sponsor: **Actimed Therapeutics Ltd** · enrollment: 120 (estimated)

## Conditions studied

- Obesity
- Muscle Loss

## Interventions

- **DRUG:** (S)-pindolol benzoate
- **DRUG:** Semaglutide
- **DRUG:** Placebo to (S)-pindolol benzoate

## Key facts

- **NCT ID:** NCT07101939
- **Lead sponsor:** Actimed Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-23
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07101939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07101939, "A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT07101939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*